Clinica Baviera
Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics in Spain and Europe. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics offers myopia, hyperopia, astigmatism, farsightedness, presbyopia, cataract, retinal, plastic surgery, pediatric ophthalmology, glaucoma, strabismus, cornea, neuro-ophthalmol… Read more
Market Cap & Net Worth: Clinica Baviera (CBAV)
Clinica Baviera (MC:CBAV) has a market capitalization of $813.70 Million (€792.71 Million) as of March 18, 2026. Listed on the MC stock exchange, this Spain-based company holds position #17821 globally and #47 in its home market, demonstrating a -0.60% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Clinica Baviera's stock price €49.50 by its total outstanding shares 16014366 (16.01 Million).
Clinica Baviera Market Cap History: 2015 to 2026
Clinica Baviera's market capitalization history from 2015 to 2026. Data shows growth from $68.35 Million to $813.70 Million (26.53% CAGR).
Clinica Baviera Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Clinica Baviera's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.95x
Clinica Baviera's market cap is 1.95 times its annual revenue
0.69x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
12.76x
Clinica Baviera's market cap is 12.76 times its annual earnings
363.13x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $68.35 Million | $85.53 Million | $4.84 Million | 0.80x | 14.12x |
| 2016 | $123.10 Million | $91.57 Million | $7.94 Million | 1.34x | 15.49x |
| 2017 | $113.90 Million | $99.88 Million | $9.88 Million | 1.14x | 11.53x |
| 2018 | $182.91 Million | $109.29 Million | $11.91 Million | 1.67x | 15.36x |
| 2019 | $199.43 Million | $124.33 Million | $12.90 Million | 1.60x | 15.46x |
| 2020 | $196.64 Million | $122.63 Million | $14.13 Million | 1.60x | 13.91x |
| 2021 | $311.04 Million | $172.73 Million | $27.93 Million | 1.80x | 11.14x |
| 2022 | $265.97 Million | $198.45 Million | $30.15 Million | 1.34x | 8.82x |
| 2023 | $363.01 Million | $224.92 Million | $36.75 Million | 1.61x | 9.88x |
| 2024 | $512.88 Million | $262.65 Million | $40.20 Million | 1.95x | 12.76x |
Competitor Companies of CBAV by Market Capitalization
Companies near Clinica Baviera in the global market cap rankings as of March 18, 2026.
Key companies related to Clinica Baviera by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Clinica Baviera Historical Marketcap From 2015 to 2026
Between 2015 and today, Clinica Baviera's market cap moved from $68.35 Million to $ 813.70 Million, with a yearly change of 26.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €813.70 Million | -0.40% |
| 2025 | €816.98 Million | +59.29% |
| 2024 | €512.88 Million | +41.28% |
| 2023 | €363.01 Million | +36.48% |
| 2022 | €265.97 Million | -14.49% |
| 2021 | €311.04 Million | +58.18% |
| 2020 | €196.64 Million | -1.40% |
| 2019 | €199.43 Million | +9.03% |
| 2018 | €182.91 Million | +60.59% |
| 2017 | €113.90 Million | -7.47% |
| 2016 | €123.10 Million | +80.09% |
| 2015 | €68.35 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Clinica Baviera was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $813.70 Million USD |
| MoneyControl | $813.70 Million USD |
| MarketWatch | $813.70 Million USD |
| marketcap.company | $813.70 Million USD |
| Reuters | $813.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.